The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer

noticia |

Loeb S., Sanda M.G., Broyles D.L., Shin S.S., Bangma C.H., Wei J.T., Partin A.W., Klee G.G., Slawin K.M., Marks L.S., van Schaik R.H.N., Chan D.W., Sokoll L.J., Cruz A.B., Mizrahi I.A., Catalona W.J.

Journal of Urology 2015

Purpose: The Prostate Health Index (phi) is a new test combining total, free and [-2]proPSA into a single score. It was recently approved by the FDA and is now commercially available in the U.S., Europe and Australia. We investigate whether phi improves specificity for detecting clinically significant prostate cancer and can help reduce prostate cancer over diagnosis. Materials and Methods: From a multicenter prospective trial we identified 658men age 50 years or older with prostate specific antigen 4 to 10 ng/ml and normal digital rectal examination who underwent prostate biopsy. In this population we compared the performance of prostate specific antigen, % free prostate specific antigen, [-2]proPSA and phi to predict biopsy results and, specifically, the presence of clinically significant prostate cancer using multiple criteria. Results: The Prostate Health Index was significantly higher in men with Gleason 7 or greater and «Epstein significant» cancer…(vermás)


1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)